Retatrutide: The “Triple G” Peptide That Could Rival Bariatric Surgery (And Why You Shouldn’t Wait)

Florida Surgery & Weight Loss | Dr. Sergey Terushkin, MD, FACS

Key Takeaways

• The “Triple Threat”: Retatrutide is the world’s first “tri-agonist,” targeting GLP-1, GIP, and Glucagon receptors simultaneously to maximize fat burning.
• Unprecedented Results: Phase 2 clinical trials show an average weight loss of 24.2% in 48 weeks—the highest ever recorded for a non-surgical treatment.
• The Glucagon Difference: Unlike Ozempic® or Mounjaro®, Retatrutide actively increases energy expenditure (calorie burning) alongside appetite suppression.
• The Timeline: FDA approval is not expected until late 2026.
• The Smart Move: Waiting two years is a metabolic risk. Starting Tirzepatide (Mounjaro) today at Florida Surgery & Weight Loss Center allows you to lose 20%+ of your body weight now and transition seamlessly to Retatrutide later.

A Surgeon’s Perspective on the Future of Weight Loss

For decades, the field of bariatric medicine had two distinct lanes: lifestyle changes (which rarely produce massive, sustained weight loss for the morbidly obese) and bariatric surgery (which is highly effective but invasive).

In the last few years, that landscape has been permanently altered. First, we saw Semaglutide (Ozempic®/Wegovy®), a single-hormone agonist that offered ~15% weight loss. Then came Tirzepatide (Mounjaro®/Zepbound™), a dual-hormone agonist pushing results closer to 21%.

Now, the medical community is buzzing about the next evolutionary leap: Retatrutide.

Often called the “Triple G” peptide, this investigational medication from Eli Lilly is showing results in clinical trials that we once thought were impossible without a scalpel. But while the future is bright, the present is powerful. Understanding exactly how this new drug works—and why it isn’t yet available—is critical for making the right decision for your health today.

What Exactly Is Retatrutide? (The “Triple G” Explained)

To understand why Retatrutide is generating such intense excitement, we have to look at the biology of how your body regulates weight.

Most modern weight-loss drugs work by mimicking natural hormones your gut produces after you eat.

1. Semaglutide (Ozempic) targets one receptor: GLP-1 (Glucagon-like peptide-1). This hormone tells your brain “I’m full” and slows the rate of stomach emptying.
2. Tirzepatide (Mounjaro) targets two receptors: GLP-1 plus GIP (Glucose-dependent insulinotropic polypeptide). GIP helps regulate fat storage and enhances the appetite-suppressing effects of GLP-1.

Retatrutide is a “tri-agonist.” It targets three distinct metabolic pathways simultaneously:

1. GLP-1: Stops the cravings and controls hunger.
2. GIP: Improves how your body breaks down sugar and fat.
3. Glucagon (The Game Changer): increases energy expenditure.

The “Secret Weapon”: Why Glucagon Matters

The addition of Glucagon is what makes Retatrutide fundamentally different from anything currently on the market. Historically, Glucagon was known mostly for raising blood sugar (the opposite of insulin). However, in this specific triple-combination, Glucagon acts as a metabolic furnace.

While GLP-1 and GIP reduce your intake (calories in), Glucagon increases your output (calories out). It signals the liver to burn stored energy and increases your resting metabolic rate. This two-pronged attack—eat less, burn more—is the “Holy Grail” of obesity medicine.

Learn About Retatrutide Dose Escalation Chart & Units Calculator for Weight Loss

The results from the Phase 2 clinical trials, published in the prestigious New England Journal of Medicine, have set a new benchmark for what is possible with pharmacotherapy.

In a 48-week study involving 338 non-diabetic adults with obesity:

• The Result: Patients on the highest dose (12mg) achieved an astonishing 24.2% average weight loss.
• The Comparison:
  • Semaglutide: ~15% loss
  • Tirzepatide: ~21% loss
  • Retatrutide: ~24%+ loss
• The 100% Club: Remarkably, 100% of participants on the highest dose lost at least 5% of their body weight. The drug worked for everyone in that group.

To put this in perspective: A patient weighing 250 pounds could potentially lose 60 pounds in less than a year on Retatrutide. Historically, losing nearly a quarter of your body weight was an outcome reserved almost exclusively for Gastric Sleeve or Gastric Bypass surgery.

The Danger of Waiting: Why “2026” is Too Far Away

Here is the hard truth: Retatrutide is not here yet. It is currently in Phase 3 trials, and FDA approval is not expected until late 2026.

I see many patients who say, “I’ll just wait for the new triple drug.” As a doctor, I strongly advise against this strategy for three reasons:

1. The “Metabolic Penalty” of Waiting

Obesity is a progressive disease. In two years, without intervention, most patients do not stay the same weight—they gain more. Gaining an additional 10–20 pounds while waiting makes your eventual journey harder and longer. Furthermore, carrying excess weight for two more years puts continued stress on your heart, joints, and liver.

2. The Tirzepatide Bridge

Tirzepatide (Mounjaro) is available right now at Florida Surgery & Weight Loss Center. It targets two of the same three receptors as Retatrutide. Patients on Tirzepatide are already losing 20% of their body weight.

• Scenario A (Wait): You start Retatrutide in 2026 at 260 lbs (after gaining 10lbs). By 2027, you might be 195 lbs.
• Scenario B (Start Now): You start Tirzepatide today at 250 lbs. By 2025, you are already 190 lbs. When Retatrutide arrives, you use it to shed the final stubborn 10-15 lbs or as a powerful maintenance tool.

3. Supply & Demand

When Retatrutide is finally approved, the demand will be astronomical. We saw widespread shortages with Wegovy and Zepbound. Patients who are already established in a medical weight loss program with a trusted provider (like our clinic) will likely have an easier time transitioning to new therapies than new patients trying to get an appointment during a shortage.

Your Best Option TODAY: Tirzepatide Medical Weight Loss

You do not need to wait for a miracle drug because we already have one.

At Florida Surgery & Weight Loss Center, our Tirzepatide (Mounjaro/Zepbound) program is delivering life-changing results every day.

Why Start Tirzepatide Now?

• Proven Efficacy: It is superior to Ozempic, with better blood sugar control and greater fat loss.
• Similar Mechanism: It prepares your body for multi-receptor therapy, effectively “priming” your receptors for the future.
• Doctor-Supervised: Unlike online “pill mills,” Dr. Terushkin monitors your labs, adjusts your dosage, and manages side effects to keep you safe.
• Immediate Availability: We have appointments available this week. You could be taking your first step toward transformation in 48 hours.

Side Effects & Safety Profile

Will Retatrutide have side effects? Yes.

In clinical trials, the side-effect profile was very similar to that of the GLP-1 medications we use today.

• Common Issues: Nausea, diarrhea, vomiting, and constipation were the most reported effects.
• Dose Escalation: These side effects were most common when the dose was increased. This highlights the importance of having a medical team manage your titration schedule rather than trying to do it alone.
• Heart Rate: Because Glucagon increases energy expenditure, some patients experienced a mild increase in heart rate. Dr. Terushkin closely monitors cardiovascular health for all patients on metabolic medications.

Comparison: The Evolution of Weight Loss Meds

Conclusion: Don’t Pause Your Life for a Clinical Trial

Retatrutide represents the exciting future of obesity medicine. It proves that help is coming for those who have struggled the most.

But your health cannot wait for 2026. Every month you wait is a month you could have spent losing weight, lowering your blood pressure, and regaining your energy.

The smartest strategy is to act now. Use the powerful tools we have available today—Tirzepatide or Semaglutide—to do the heavy lifting. Then, when Retatrutide arrives, you won’t be starting from scratch; you will be crossing the finish line.

Frequently Asked Questions (FAQ)

Start Your Transformation TODAY (Not in 2026)

Ready to lose 20% of your body weight? The technology exists now.

Florida Surgery and Weight Loss Center Dr. Sergey Terushkin, MD, FACS

📞 (954) 551-3508 📍 1911 Harrison Street, Hollywood, FL 33020

Disclaimer: Retatrutide is an investigational drug and is NOT yet FDA-approved. All information presented is based on current clinical trial data. Consult Dr. Terushkin for FDA-approved treatments available now